Glanzmann thrombasthenia: An update

Clinica Chimica Acta

Volumn 411, Issue 1-2, 2010, Pages 1-6

  Franchini, Massimo ^a   Favaloro, Emmanuel J ^b   Lippi, Giuseppe ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Bleeding; Glanzmann thrombasthenia; GPIIb IIIa; rFVIIa; Treatment

Indexed keywords

ANTIFIBRINOLYTIC AGENT; FIBRINOGEN RECEPTOR; PLASMA PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

AUTOSOMAL RECESSIVE DISORDER; BLEEDING; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; CLINICAL FEATURE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FLOW CYTOMETRY; GENE MUTATION; GLANZMANN DISEASE; HUMAN; LABORATORY DIAGNOSIS; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SKIN BRUISING; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; THROMBASTHENIA;

EID: 70449522889     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.10.016     Document Type: Review

References (52)

1. Salles I.I., Feys H.B., Iserbyt B.F., De Meyer S.F., Vanhoorelbeke K., and Deckmyn H. Inherited traits affecting platelet function. Blood Rev 22 (2008) 155-172
2. Nurden A.T. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemostasis 3 (2005) 1773-1782
3. Nurden A.T. Glanzmann thrombasthenia. Orphan J Rare Dis 1 (2006) 10
4. Nurden P., and Nurden A.T. Congenital disorders associated with platelet dysfunctions. Thromb Haemost (2008) 253-263
5. Glanzmann E. Hereditare hamorrhagische thrombasthenie. Ein Beitrag zur Pathologie der Blutplattchen. J Kinderkrankenschwester 88 (1918) 113
6. George J.N., Caen J.P., and Nurden A.T. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 75 (1990) 1383-1395
7. Rosenberg N., Yatuv R., Sobolev V., Peretz H., Zivelin A., and Seligsohn U. Major mutations in calf-1 and calf-2 domains of glycoprotein IIb in patients with Glanzmann thrombasthenia enable GPIIb/IIIa complex formation, but impair its transport from the endoplasmic reticulum to the Golgi apparatus. Blood 101 (2003) 4808-4815
8. Nurden A.T., Fiore M., Pillois X., and Nurden P. Genetic testing in the diagnostic evaluation of inherited platelet disorders. Semin Thromb Hemost 35 (2009) 204-212
9. French D.L., and Seligsohn U. Platelet glycoprotein IIb/IIIa receptors and Glanzmann's thrombasthenia. Arterioscler Thromb Vasc Biol 20 (2000) 607-610
10. Miller J.L. Glycoprotein analysis for the diagnostic evaluation of platelet disorders. Semin Thromb Hemost 35 (2009) 224-232
11. Favaloro E.J. Genetic testing for von Willebrand disease: the case against. J Thromb Haemostasis (2009) 10.1111/j.1538-7836.2009.03482.x
12. Lippi G., and Favaloro E.J. The missing link between genotype, phenotype and clinics. Biochemia Med 19 (2009) 137-145
13. Milet-Marsal S., Breillat C., and Peyruchaud O. Analysis of the amino acid requirement for a normal αIIbß3 maturation at αIIbGlu324 commonly mutated in Glanzmann thrombasthenia. Thromb Haemost 88 (2002) 655-662
14. Gonzalez-Manchon C., Arias-Salgado E.G., and Butta N. A novel homozygous splice junction mutation in GPIIb associated with alternative splicing, nonsense-mediated decay of GPIIb-mRNA, and type II Glanzmann's thrombasthenia. J Thromb Haemostasis 1 (2003) 1071-1078
15. Franchini M., Lippi G., Veneri D., Targher G., Zaffanello M., and Guidi G.C. Inherited platelet disorders. Clin Chim Acta 387 (2008) 1-8
16. Guidi G.C., and Lippi G. Will "personalized medicine" need personalized laboratory approach?. Clin Chim Acta 400 (2009) 25-29
17. Briggs C., Harrison P., and Machin S.J. Continuing developments with the automated platelet count. Int J Lab Hematol 29 (2007) 77-91
18. Kottke-Marchant K., and Corcoran G. The laboratory diagnosis of platelet disorders. Arch Pathol Lab Med 126 (2002) 133-146
19. Mezzano D., Quiroga T., and Pereira J. The level of laboratory testing required for diagnosis or exclusion of a platelet function disorder using platelet aggregation and secretion assays. Semin Thromb Hemost 35 (2009) 242-254
20. Lippi G., Favaloro E.J., Salvagno G.L., and Franchini M. Laboratory assessment and perioperative management of patients on antiplatelet therapy: from the bench to the bedside. Clin Chim Acta 405 (2009) 8-16
21. Lippi G., Favaloro E.J., Franchini M., and Guidi G.C. Milestones and perspectives in coagulation and hemostasis. Semin Thromb Hemost 35 (2009) 9-22
22. Favaloro E.J. Clinical application of the PFA-100. Curr Opin Hematol 9 (2002) 407-415
23. Favaloro E.J. Clinical utility of the PFA-100. Semin Thromb Hemost 34 (2008) 709-733
24. McGlasson D.L., and Fritsma G.A. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost 35 (2009) 168-180
25. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 35 (2009) 158-167
26. Kiyoi T., Tomiyama Y., and Honda S. A naturally occurring Tyr143His alpha IIb mutation abolishes alpha IIb beta 3 function for soluble ligands but retains its ability for mediating cell adhesion and clot retraction: comparison with other mutations causing ligand-binding defects. Blood 101 (2003) 3485-3491
27. Weiss H.J. Impaired platelet procoagulant mechanisms in patients with bleeding disorders. Semin Thromb Hemost 35 (2009) 233-241
28. Linden M.D., Frelinger III A.L., et al. Application of flow cytometry to platelet disorders. Semin Thromb Hemost 30 (2004) 501-511
29. Michelson A.D. Flow cytometric analysis of platelet surface glycoproteins: phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia. J Lab Clin Med 110 (1987) 346-354
30. Jennings L.K., Ashmun R.A., Wang W.C., and Dockter M.E. Analysis of human platelet glycoproteins IIb-IIIa and Glanzmann's thrombasthenia in whole blood by flow cytometry. Blood 68 (1986) 173-179
31. Goodall A.H., and Appleby J. Flow-cytometric analysis of platelet-membrane glycoprotein expression and platelet activation. Methods Mol Biol 272 (2004) 225-253
32. Shattil S.J., Cunningham M., and Hoxie J.A. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 70 (1987) 307-315
33. Male C., Koren D., Eichelberger B., Kaufmann K., and Panzer S. Monitoring survival and function of transfused platelets in Glanzmann thrombasthenia by flow cytometry and thrombelastography. Vox Sang 91 (2006) 174-177
34. Vijapurkar M., Ghosh K., Shetty S., McLane M.A., Moura da Silva A.M., and Butera D. A simple, novel and robust test to diagnose type I Glanzmann thrombasthenia. Haematologica 93 (2008) 797-798
35. Garcia A. Proteome analysis of signaling cascades in human platelets. Blood Cells Mol Dis 36 (2006) 152-156
36. Kottke-Marchant K., and Corcoran G. The laboratory diagnosis of platelet disorders. Arch Pathol Lab Med 126 (2002) 133-146
37. Hayward C.P.M., Rao A.K., and Cattaneo M. Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment. Haemophilia 12 Suppl. 3 (2006) 128-136
38. Poon M.C., D'Oiron R., Von Depka M., et al. International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group: prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemostasis 2 (2004) 1096-1103
39. Poon M.C., Zotz R., Di Minno G., Abrams Z.S., Knudsen J.B., and Laurian Y. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol 43 1 Suppl 1 (2006) S33-S36
40. Franchini M. The use of recombinant activated factor VII in platelet disorders: a critical review of the literature. Blood Transfus 7 (2009) 24-28
41. Poon M.C. The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transfus Med Rev 21 (2007) 223-236
42. Hers I., and Mumford A. Understanding the therapeutic action of recombinant factor VIIa in platelet disorders. Platelets 19 (2008) 571-581
43. Tengborn L., and Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 75 (1996) 981-982
44. Chuansumrit A., Sangkapreecha C., and Hathirat P. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost 82 (1999) 1778
45. Poon M.C., Demers C., Jobin F., and Wu J.W. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 94 (1999) 3951-3953
46. Poon M.C., d'Oiron R., Hann I., et al. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol 38 (2001) 21-25
47. Caglar K., Cetinkaya A., Aytac S., Gumruk F., and Gurgey A. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 20 (2003) 435-438
48. Chuansumrit A. Confirmation of high dose recombinant factor VIIa in treating patients with Glanzmann thrombasthenia. J Thromb Haemostasis 1 (2003) 396
49. Chuansumrit A., Suwannuraks M., Sri-Udomporn N., Pongtanakul B., and Worapongpaiboon S. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 14 (2003) 187-190
50. Almeida A., Khair K., Hann I., and Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 121 (2003) 477-481
51. d'Oiron R., Menart C., Trzeciak M.C., et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thromboasthenia undergoing invasive procedures. Thromb Haemost 83 (2000) 644-647
52. Valentino L.A. Use of rFVIIa in 4 children with Glanzmann Thromboasthenia. J Pediatr Hematol Oncol 28 (2004) 653-658